Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Avalo Therapeuticsavalotx.com · Low evidenceAvalo Therapeutics is a clinical-stage biotechnology company developing IL-1β-based treatments for immune-mediated inflammatory diseases. Its lead asset, abdakibart (AVTX-009), recently reported positive topline data from a Phase 2 trial in moderate to severe hidradenitis suppurativa.
Parse Score